Neuberger Berman Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Neuberger Berman Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,228	Closed	-$883K	–	1906
2023 Q1	$883K	Buy	8,228 +409	+5%	+$47.1K	﹤0.01%	1291
2022 Q4	$860K	Buy	+7,819	New	+$507K	﹤0.01%	1278

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group's RXDX Position: Q2 2023 in Review

Neuberger Berman Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 8,228 shares — an estimated $883K sold.

Neuberger Berman Group first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $883K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Neuberger Berman Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Neuberger Berman Group sold 8,228 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $883K.
Neuberger Berman Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Neuberger Berman Group's Prometheus Biosciences, Inc. Common Stock position peaked at $883K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Neuberger Berman Group's 13F filing for Q2 2023, filed 11 Aug 2023.